This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
Scientific Reports Open Access 27 December 2019
-
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
Leukemia Open Access 12 March 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 2013; 369: 2391–2405.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013; 369: 2379–2390.
Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W . The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2013; e-pub ahead of print 13 November 2013; doi:10.1038/leu.2013.337.
Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.
Itzykson R, Fenaux P . Epigenetics of myelodysplastic syndromes. Leukemia 2013; e-pub ahead of print 13 December 2013; doi:10.1038/leu.2013.343.
Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128–1138.
Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119: 559–568.
Teasdale RD, Jackson MR . Signal-mediated sorting of membrane proteins between the endoplasmic reticulum and the golgi apparatus. Annu Rev Cell Dev Biol 1996; 12: 27–54.
Acknowledgements
This work was partially sponsored by grants NSC 100-2314-B002-057-MY3, NSC 100-2314-B-002 -112 -MY3 and NSC 100-2628 -B-002-003-MY3 from the National Science Council (Taiwan), MOHW103-TD-B-111-04 from the Ministry of Health and Welfare (Taiwan), and NTUH 102P06 and UN 102-015 from the Department of Medical Research, National Taiwan University Hospital.
Author contributions
H-AH and Y-YK were responsible for study design, literature collection, data management and interpretation, statistical analysis and manuscript writing; P-HC and W-CC were responsible for mutation analysis and interpretation; H-FT planned, designed and coordinated the study over the entire period and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hou, HA., Kuo, YY., Chou, WC. et al. Calreticulin mutation was rarely detected in patients with myelodysplastic syndrome. Leukemia 28, 1555–1557 (2014). https://doi.org/10.1038/leu.2014.71
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.71
This article is cited by
-
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
Scientific Reports (2019)
-
Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis
Annals of Hematology (2017)
-
Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia
Annals of Hematology (2015)
-
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
Leukemia (2014)
-
Low frequency of calreticulin mutations in MDS patients
Leukemia (2014)